Evorpacept单药及联合帕博利珠单抗或曲妥珠单抗治疗晚期实体瘤患者(ASPEN-01):一项首次人体、开放标签、多中心、1期剂量递增和剂量扩展研究
这项首次人体1期研究在晚期实体瘤患者中评估了CD47阻断蛋白evorpacept单药及联合帕博利珠单抗或曲妥珠单抗的安全性、药代动力学和抗肿瘤活性。110例患者接受治疗,未达到最大耐受剂量,最高给药剂量为10 mg/kg每周一次或30 mg/kg每两周一次;联合治疗在头颈鳞癌、胃/胃食管结合部癌和非小细胞肺癌中观察到初步抗肿瘤活性。
要点
- Evorpacept单药未达到最大耐受剂量,最高给药剂量为10 mg/kg每周一次或30 mg/kg每两周一次。
- 剂量扩展采用evorpacept 10 mg/kg每周一次联合帕博利珠单抗或曲妥珠单抗。
- 联合治疗在头颈鳞癌、胃/胃食管结合部癌和非小细胞肺癌中观察到初步抗肿瘤活性。
核心结论
- 安全性结果支持evorpacept联合帕博利珠单抗或曲妥珠单抗用于晚期实体瘤患者。
- 初步抗肿瘤活性结果支持未来在头颈鳞癌、胃或胃食管结合部癌及非小细胞肺癌中进一步研究evorpacept联合帕博利珠单抗或曲妥珠单抗。
研究设计与样本
- 首次人体、开放标签、多中心、1期剂量递增和剂量扩展研究,在美国和韩国的九家医院和一家诊所进行。
- 剂量递增和安全性导入阶段纳入年龄18岁及以上、组织学或细胞学确诊的晚期或转移性实体瘤、无可用标准治疗、按RECIST 1.1版可测量或不可测量疾病、ECOG体能状态评分为0或1的患者。
- 剂量递增阶段采用3+3设计,evorpacept静脉给药0.3、1、3或10 mg/kg每周一次(21天周期),或30 mg/kg每两周一次(28天周期)。
- 安全性导入阶段给予剂量递增阶段确定的最大耐受剂量evorpacept联合静脉帕博利珠单抗200 mg每3周一次或静脉曲妥珠单抗8 mg/kg负荷剂量后6 mg/kg每3周一次。
- 剂量扩展阶段纳入年龄18岁及以上、二线或后线晚期恶性肿瘤患者,头颈鳞癌和非小细胞肺癌患者接受最大耐受剂量evorpacept联合帕博利珠单抗200 mg每3周一次,HER2阳性胃或胃食管结合部癌患者接受最大耐受剂量evorpacept联合曲妥珠单抗8 mg/kg负荷剂量后6 mg/kg每3周一次。
主要发现
- 2017年3月6日至2019年2月21日,110例患者接受单药evorpacept(n=28)、evorpacept联合帕博利珠单抗(n=52)或evorpacept联合曲妥珠单抗(n=30),纳入安全性分析。
- 中位随访时间:单药组29.1个月(95%CI不可计算[NC]-NC),evorpacept联合帕博利珠单抗组27.0个月(25.1-28.8),evorpacept联合曲妥珠单抗组32.7个月(27.0-32.7)。
- 单药evorpacept组报告2例(7%)第一周期剂量限制性毒性:1例胃食管结合部癌患者接受3 mg/kg每周一次后出现中性粒细胞减少伴相关感染,1例胰腺癌患者接受30 mg/kg每两周一次后出现血小板减少伴相关出血。
- 未达到最大耐受剂量;最高给药剂量为10 mg/kg每周一次或30 mg/kg每两周一次;剂量扩展队列采用10 mg/kg每周一次联合帕博利珠单抗或曲妥珠单抗。
- 最常见的3级或以上治疗相关不良事件:单药evorpacept组为血小板减少(2例[7%]),evorpacept联合帕博利珠单抗组为血小板减少(2例[4%]),evorpacept联合曲妥珠单抗组为血小板减少(2例[7%])和中性粒细胞减少(2例[7%])。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both innate and adaptive immune responses are important components of anticancer immunity. The CD47-SIRPα interaction could represent an important pathway used by tumour cells to evade immune surveillance. We aimed to evaluate the safety, pharmacokinetics, pharmacodynamics, and anticancer activity of evorpacept (also known as ALX148), a high-affinity CD47-blocking protein with an inactive IgG Fc region in patients with solid tumours. METHODS: We did a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study at nine hospitals and one clinic in the USA and Korea. Eligible patients for the dose-escalation and safety lead-in phases were aged 18 years or older with histological or cytological diagnosis of advanced or metastatic solid tumours with no available standard therapy, measurable or unmeasurable disease according to the Response Evaluation Criteria in Solid Tumors version 1.1, and an Eastern Cooperative Oncology Group performance status score of 0 or 1. In the dose-escalation phase, which used a 3 + 3 design, patients received intravenous evorpacept at either 0·3, 1, 3, or 10 mg/kg once per week in 21-day cycles, or 30 mg/kg once every other week in 28-day cycles. In the safety lead-in phase, patients were given the maximum tolerable dose of evorpacept from the dose-escalation phase plus either intravenous pembrolizumab (200 mg administered once every 3 weeks) or intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks). In the dose-expansion phase, additional patients aged 18 years or older with second-line or later-line advanced malignancies were enrolled into three parallel cohorts: those with head and neck squamous cell carcinoma (HNSCC) and those with non-small-cell lung cancer (NSCLC) were given the maximum tolerated dose of evorpacept plus intravenous pembrolizumab (200 mg administered once every 3 weeks), and patients with HER2-positive gastric or gastroesophageal junction cancer were given the maximum tolerated dose of evorpacept plus intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks) until disease progression, voluntary withdrawal from the study, or unacceptable toxicity. The primary endpoint was the maximum tolerated dose of evorpacept administered as a single agent and in combination with pembrolizumab or trastuzumab, measured by the occurrence of dose-limiting toxicities during the first cycle, and was assessed in all patients who had received at least one dose of evorpacept. Secondary outcomes included the safety, tolerability, and antitumour activity of evorpacept, alone or in combination with pembrolizumab or trastuzumab. The primary outcome, safety, and tolerability were assessed in all patients who had received at least one dose of evorpacept, and antitumour activity was assessed in those who recieved at least one dose of study treatment and underwent at least one post-baseline tumor assessment. This trial is registered with ClinicalTrials.gov, NCT03013218. FINDINGS: Between March 6, 2017, and Feb 21, 2019, 110 patients received single-agent evorpacept (n=28), evorpacept plus pembrolizumab (n=52), or evorpacept plus trastuzumab (n=30), and were included in the safety analysis. Median follow-up was 29·1 months (95% CI not calculable [NC]-NC) in the single-agent cohort, 27·0 months (25·1-28·8) in the evorpacept plus pembrolizumab cohort, and 32·7 months (27·0-32·7) in the evorpacept plus trastuzumab cohort. Two (7%) dose-limiting toxicities in the first cycle were reported in patients who received single-agent evorpacept; neutropenia with an associated infection in one patient with gastroesophageal junction cancer who received 3 mg/kg once per week, and thrombocytopenia with associated bleeding in one patient with pancreatic cancer who received 30 mg/kg once every other week. No maximum tolerated dose was reached; the maximum administered doses were 10 mg/kg once per week or 30 mg/kg once every other week. The 10 mg/kg once per week dose was used in the expansion cohorts in combination with pembrolizumab or trastuzumab. The most common grade 3 or worse treatment-related adverse events were thrombocytopenia with single-agent evorpacept (two [7%] patients) and evorpacept plus pembrolizumab (two [4%]), and thrombocytopenia (two [7%]) and neutropenia (two [7%]) with evorpacept plus trastuzumab. In patients who received single-agent evorpacept, four treatment-related serious adverse events were reported. Five serious treatment-related adverse events related to evorpacept plus pembrolizumab were reported, and one serious adverse event related to evorpacept plus trastuzumab was reported. In response-evaluable patients in the dose-escalation phase (n=15) receiving single-agent evorpacept once per week, four (27%) had a best overall response of stable disease (two received 0·3 mg/kg, one received 3 mg/kg, and one received 10 mg/kg); in the 11 patients who received single-agent evorpacept at the highest dose of 30 mg/kg once every other week, two (18%) had stable disease. In the dose-expansion cohort, overall responses were recorded in four (20·0%; 95% CI 5·7-43·7) of 20 patients with HNSCC who received evorpacept plus pembrolizumab, in one (5·0%; 0·1-24·9) of 20 patients with NSCLC who received evorpacept plus pembrolizumab, and in four (21·1%; 6·1-45·6) of 19 patients with gastric or gastroesophageal junction cancer who received evorpacept plus trastuzumab. INTERPRETATION: The safety findings support the use of evorpacept in combination with pembrolizumab or trastuzumab for patients with advanced solid tumours. Preliminary antitumour activity results support future investigation of evorpacept combined with pembrolizumab or trastuzumab in patients with HNSCC, gastric or gastroesophageal junction cancer, and NSCLC. FUNDING: ALX Oncology.
引用
- Lakhani NJ, Chow LQM, Gainor JF, et al. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021. PMID: 34793719. doi:10.1016/S1470-2045(21)00584-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。